Cormorant Asset Management, LP Revolution Medicines, Inc. Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$17.68 - $25.53 $1.77 Million - $2.55 Million	-100,000 Reduced 5.01%	1,895,066 $45.1 Million
Q1 2022 May 16, 2022	SELL	$17.31 - $26.4 $7.56 Million - $11.5 Million	-436,786 Reduced 17.96%	1,995,066 $50.9 Million
Q4 2021 Feb 14, 2022	SELL	$24.35 - $33.7 $17.4 Million - $24 Million	-712,848 Reduced 22.67%	2,431,852 $61.2 Million
Q3 2021 Nov 15, 2021	SELL	$23.95 - $33.41 $4.63 Million - $6.46 Million	-193,466 Reduced 5.8%	3,144,700 $86.5 Million
Q2 2021 Aug 16, 2021	BUY	$29.0 - $47.44 $23.6 Million - $38.6 Million	813,166 Added 32.2%	3,338,166 $106 Million
Q1 2021 May 17, 2021	BUY	$37.21 - $54.43 $1.11 Million - $1.63 Million	29,934 Added 1.2%	2,525,000 $116 Million
Q4 2020 Feb 16, 2021	SELL	$30.19 - $45.49 $4.38 Million - $6.6 Million	-145,111 Reduced 5.5%	2,495,066 $98.8 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $34.8 $79,496 - $122,356	3,516 Added 0.13%	2,640,177 $91.9 Million
Q2 2020 Aug 14, 2020	SELL	$19.65 - $39.34 $2.56 Million - $5.13 Million	-130,417 Reduced 4.71%	2,636,661 $82.7 Million
Q1 2020 May 15, 2020	BUY	$20.0 - $34.08 $55.3 Million - $94.3 Million	2,767,078 New	2,767,078 $60.6 Million

297

168M

920K

1.06M

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.2B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.